Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

Rhea-AI Summary

VolitionRx (NYSE AMERICAN: VNRX) is participating in a webinar hosted by Edison Group to discuss new data on the potential use of Nu.Q® NETs in sepsis management. The data, presented at ESICM LIVES 2024, includes three independent studies involving over 3000 patients and more than 14,000 patient samples. The webinar, scheduled for October 21, 2024, at 10:00 AM ET, will feature updates from Volition's Chief Medical Officer and Chief Commercial Officer.

The presentation will focus on the role of H3.1 nucleosomes in NETosis, the implications of elevated H3.1 levels in sepsis patients, and the potential of Nu.Q® NETs biomarker to predict organ failure. Volition's Nu.Q® NETs technology quantifies circulating H3.1 nucleosomes in the bloodstream, serving as a surrogate marker for Neutrophil Extracellular Traps (NETs). The company aims to develop simple, cost-effective blood tests for diagnosing and monitoring various diseases, including cancer, in both humans and animals.

Positive

• Volition is presenting data from three large independent studies on Nu.Q® NETs in sepsis management
• The studies involved over 3000 patients and more than 14,000 patient samples
• Nu.Q® NETs biomarker shows potential to predict organ failure in sepsis patients
• The new data supports ongoing licensing discussions with key industry players

Negative

• None.

HENDERSON, Nev., Oct. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expound new data, presented at ESICM LIVES 2024, the annual congress of the European Society of Intensive Care Medicine, earlier this week.

 

 

Given the extensive size and scope of the three independent studies on the potential use of Nu.Q® NETs in sepsis management, which included over 3000 patients and more than 14,000 patient samples, the webinar aims to provide stakeholders with a comprehensive understanding of the data and offer insights into how Volition's nucleosome quantification technology could be used in clinical practice.

The webinar takes place on Monday, October 21, at 10:00 AM U.S. Eastern Time and will include updates from Volition's Dr. Andrew Retter (Chief Medical Officer) and Mr. Gael Forterre (Chief Commercial Officer).

Dr. Andrew Retter said:

"During our upcoming webinar, we will undertake a deep dive into the data presented at ESICM 2024, highlighting research findings from large independent studies on the potential use of our Nu.Q® NETs H3.1 assay to enhance sepsis management in clinical practice.

"We will explore the role of the role of H3.1 nucleosomes in NETosis; why elevated levels of H3.1 are a cause for concern in sepsis patients and examine how the Nu.Q® NETs biomarker has the potential to predict organ failure."

Gael Forterre, Volition's Chief Commercial Officer, added:

"The findings from these latest Nu.Q® NETs studies are vital to our commercialization efforts and will support our ongoing licensing discussions with key industry players." 

Nu.Q® NETs, Volition's nucleosome quantification technology, is a simple, low-cost, accessible test that quantifies an individual's level of circulating H3.1 nucleosomes in the bloodstream, a surrogate marker for Neutrophil Extracellular Traps (NETs). Although NETs play a critical role in our normal immune response, elevated levels of NETs can lead to tissue damage, and in severe cases, sepsis, organ failure and death.

The Nu.Q® NETs panel and Q&A event is being hosted by Soo Romanoff (Managing Director, Healthcare) at Edison Group.

Event Details:

Title: Volition Nu.Q® NETs Data Insights Webinar
Date: Monday October 21, 2024
Time: 10:00 AM U.S Eastern
Register at: Edison Registration

To register for Volition's Data Insights webinar click here. The event will be recorded and available afterward on demand.

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's technology go to: www.volition.com.

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life. For more information about Volition's technology go to: www.volition.com.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore. 

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the potential uses, benefits and effectiveness of Volition's Nu.Q® technology platform. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. 

Video: https://www.youtube.com/watch?v=ZX-d95V8UfQ

Media Enquiries: 
Louise Batchelor/Debra Daglish
Volition 
mediarelations@volition.com
+44 (0)7557 774620

View original content to download multimedia:https://www.prnewswire.com/news-releases/volition-to-share-new-nets-in-sepsis-management-data-insights-at-upcoming-webinar-302271463.html

SOURCE VolitionRx Limited

FAQ

What is the purpose of Volition's upcoming webinar on October 21, 2024?

The webinar aims to discuss new data on the potential use of Nu.Q® NETs in sepsis management, presented at ESICM LIVES 2024, and provide insights into how Volition's nucleosome quantification technology could be used in clinical practice.

How many patients were involved in the studies on Nu.Q® NETs presented by VNRX?

The three independent studies on the potential use of Nu.Q® NETs in sepsis management included over 3000 patients and more than 14,000 patient samples.

What does Volition's Nu.Q® NETs technology measure?

Nu.Q® NETs technology quantifies an individual's level of circulating H3.1 nucleosomes in the bloodstream, which serves as a surrogate marker for Neutrophil Extracellular Traps (NETs).

How could the Nu.Q® NETs biomarker potentially benefit sepsis patients?

The Nu.Q® NETs biomarker has the potential to predict organ failure in sepsis patients, which could enhance sepsis management in clinical practice.